You are here

Semin Hematol DOI:10.1053/j.seminhematol.2014.05.004

Evolving understanding of the CLL genome.

Publication TypeJournal Article
Year of Publication2014
AuthorsGruber, M, Wu, CJ
JournalSemin Hematol
Volume51
Issue3
Pages177-87
Date Published2014 Jul
ISSN1532-8686
KeywordsChromosome Aberrations, Epigenomics, Genetic Heterogeneity, Genome, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, Antigen, B-Cell, Signal Transduction
Abstract

Over the past few years, massively parallel sequencing technologies have revealed with high resolution the tremendous genetic and epigenetic heterogeneity in chronic lymphocytic leukemia (CLL). We have learned how the molecular architecture differs not only between affected individuals but also within samples and over time. These insights have catalyzed our understanding of the pathobiology of CLL and point to critical signaling pathways in the development and progression of the disease. Several key driver alterations have been identified, which serve to refine prognostic schemata but also to inspire the development of new therapeutic strategies. Ongoing advances in technology promise to further elucidate the molecular basis of CLL, and this knowledge is anticipated to aid us in understanding and addressing the clinical challenge presented by the vast variability in the clinical course of patients with CLL.

DOI10.1053/j.seminhematol.2014.05.004
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/25048782?dopt=Abstract

Alternate JournalSemin. Hematol.
PubMed ID25048782
PubMed Central IDPMC4107366
Grant List1R01HL103532-01 / HL / NHLBI NIH HHS / United States
R01 CA182461 / CA / NCI NIH HHS / United States
R01 HL103532 / HL / NHLBI NIH HHS / United States
R01 CA155010 / CA / NCI NIH HHS / United States
1R01CA155010-01A1 / CA / NCI NIH HHS / United States
R01 HL116452 / HL / NHLBI NIH HHS / United States